Physician profile
Javed Masoud
NPI 1376592451
$2,198.83
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $577 · 2020: $490 · 2021: $573 · 2022: $322 · 2023: $236.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $236.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $236.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $445.59 | 2019-2023 | Ozempic |
| Glaxosmithkline, LLC. | $342.12 | 2019-2022 | |
| Amarin Pharma, INC. | $281.03 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $194.06 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $183.83 | 2020-2023 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $183.18 | 2020-2023 | Eliquis, Camzyos |
| Lilly USA, LLC | $111.45 | 2019-2023 | Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $80.19 | 2019-2021 | |
| Medtronic, INC. | $72.18 | 2021 | |
| Pfizer INC. | $61.78 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $60.94 | 2019-2023 | Breztri |
| Amgen INC. | $49.27 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $36.37 | 2019 | |
| Sanofi-Aventis U.S. LLC | $34.15 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $27.45 | 2023 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $23.66 | 2022 | |
| Abbott Laboratories | $11.58 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Javed Masoud listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.